Assessment of the expression patterns of ZNF667-AS1, LINC00662, and ZFP36 and their association with breast cancer patients’ clinicopathological

Abstract

Abstract Background: Among women worldwide, breast cancer is the most common form of cancer. Malignant tumors are believed to be regulated by long noncoding RNAs (lncRNAs). By using both experimental and bioinformatic approaches, we examined the expression level of ZNF667-AS1 and its interactions with correlated microRNAs, lncRNAs, and mRNAs or protein-coding genes. Material and methods: An RNA interaction analysis (miRWalk, lncRRisearch, ENCORI, and lncBase3) was performed along with a protein interaction analysis (STRING). As part of this study, we analyzed the differentially expressed genes inthe microarray dataset GSE61304, as well as in breast cancer tissue samples,using quantitative real-time PCR. Result:Significantly low expression of ZNF667-AS1 was found in the ENCORI experiment (change: 0.61, FDR < 0.0001) and qRT-PCR experiment (fold change: 0.046071, p value < 0.0001). The ROC curve indicates that ZNF667-AS1 has potential as a diagnostic biomarker of breast cancer(AUC of 0.8373, p value <0.0001). ZNF667-AS1 interacts with mRNA ZFP36, lncRNA LINC0062, and hsa-miR-877-5p. Among the breast carcinoma samples studied, ZFP36 had a low level of expression (FC=0.573951, P-value=0.0027), Linc00662 had a high level of expression (FC=2.291036, P-value=0.0007) and based on ENCORI, hsa-miR-877-5p had a severe level of expression. Linc00662 (AUC of 0.6864, P-value= 0.0211) and ZFP36 (AUC of 0.7692, P-value= 0.0009) are two potential biomarkers for BC diagnosis. Conclusion: ZNF667-As1 was found to be a promising diagnostic biomarker for breast cancer samples based on this integrated computational and experimental study. In the future, researchers will be able to gain more insight into the role ZNF667-AS1 plays in breast cancer by investigating the correlation between ZNF667-AS1 and correlated mRNAs, lncRNAs, and microRNAs, especially the RNAs mentioned in this study.